Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
about
Evolutionary scalpels for dissecting tumor ecosystems.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
P2860
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@en
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@nl
type
label
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@en
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@nl
prefLabel
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@en
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@nl
P2093
P2860
P1476
Combination of Imatinib Mesyla ...... astrointestinal Stromal Tumor.
@en
P2093
Andrew K Godwin
Harsh B Pathak
Karthik Devarajan
Lawrence Gersz
Martin G Belinsky
Phillip Zook
P2860
P304
P356
10.1158/1078-0432.CCR-16-0529
P407
P577
2016-07-01T00:00:00Z